A Single Blind, Randomised, Placebo Controlled, Repeat Dose, Dose Escalating Study Investigating Safety, Tolerability Pharmacokinetics, Pharmacodynamics and the Beta-Cell Preserving Effect of Otelixizumab in New-Onset, Autoimmune Type 1 Diabetes Mellitus Patients
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 03 Oct 2017
At a glance
- Drugs Otelixizumab (Primary)
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions
- Sponsors GlaxoSmithKline
- 28 Sep 2017 Planned primary completion date changed from 26 Sep 2018 to 26 Oct 2018.
- 19 Jun 2017 Planned End Date changed from 26 Sep 2018 to 27 Sep 2021.
- 10 Jun 2017 Biomarkers information updated